Vassilis I Zannis

7309606, Dec 18, 2007

Sep 7, 2005

11/220485

Vassilis I. Zannis - Newton MA, US
Kypreos E. Kyriakos - Ialyssos-Rhodes, GR

The Trustees of Boston University - Boston MA
KOS Pharmaceuticals, Inc. - Miami FL

C12N 15/00
C07K 14/00
C07K 1/00

435440, 530350, 530359

The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e. g. , apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having hypercholesterolemia, reduces the plasma cholesterol levels without inducing hypertriglyceridemia. The invention also provides a method for reducing plasma cholesterol using low doses of naturally-occurring apoE proteins.

20020123093, Sep 5, 2002

Apr 5, 2001

09/827854

Vassilis Zannis - Newton MA, US
Kyriakos Kypreos - Rhodes, GR

C12P021/02
C07H021/04
C12N005/06
C07K014/775

435/069100, 435/325000, 435/320100, 536/023500, 530/359000

This invention provides methods of lowering cholesterol, delaying the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia. These methods involve administrating to or expressing in a mammal, an apoE polypeptide or nucleic acid that, when administered to or expressed in a mammal, lowers the total serum cholesterol level without inducing hypertriglyceridemia.

20060142200, Jun 29, 2006

Feb 24, 2006

11/361788

Vassilis Zannis - Newton MA, US
Kyriakos Kypreos - Ialyssos-Rhodes, GR

A61K 38/17
C07K 14/775

514012000, 530359000

This invention provides methods of lowering cholesterol, delaying the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia. These methods involve administrating to or expressing in a mammal, an apoE polypeptide or nucleic acid that, when administered to or expressed in a mammal, lowers the total serum cholesterol level without inducing hypertriglyceridemia.

20080064652, Mar 13, 2008

Sep 7, 2007

11/899700

Vassilis Zannis - Newton MA, US
Kypreos Kyriakos - Ialyssos-Rhodes, GR

A61K 31/7052
A61P 9/10
C07H 21/00

514044000, 536023500

The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e.g., apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having hypercholesterolemia, reduces the plasma cholesterol levels without inducing hypertriglyceridemia. The invention also provides a method for reducing plasma cholesterol using low doses of naturally-occurring apoE proteins.

58770097, Mar 2, 1999

Dec 28, 1993

8/174672

Vassilis I. Zannis - Newton MA
Christos Cladaras - Needham MA

Trustees of Boston University - Boston MA

C12N 1563
C12N 1511

4353201

The present invention provides isolated apolipoprotein transcription factors and gene regulatory elements. The invention also provides methods of modulating apolipoprotein gene expression by interfering with interactions between apolipoprotein transcription factors and their cognate regulatory elements and/or by interfering with protein-protein interactions between or among apolipoprotein transcription factors or between an apolipoprotein transcription factor and the transcription machinery. This invention has application in the treatment of disorders relating to lipid metabolism (e. g. atherosclerosis, hypertriglyceridemia, etc. ).